Our organization is based on interactions between all entities composing the network: investigators, industries, patients, scientists.
We are all “working together” to improve patient outcomes!
The role of the Operational Team is to manage the day-to-day activities.
The Steering Committee has the responsibility of strategic decisions and is composed of one representative per Oncodistinct center.
The Coordinating Team is composed of physicians elected by the Steering Committee and implements the decisions of the Steering Committee.
The driving force of the Oncodistinct Network is firmly its Investigators’ Think Tank. It is the forum for scientific discussions, ideas and strategies which brings innovative clinical research projects. The think tank is composed by a large panel of experts in cancer care (investigators, scientists…) involved in drug development.
To be more efficient and to work on different topics, each member can choose to join a working group. The aim of the working groups is to share thoughts and ideas in order to develop future innovative studies for the Network.
“Out of the box” projects are encouraged among all these WGs, with innovative, original trial designs, treatment strategies and topics.
The results of the discussions are shared at each biannual Oncodistinct meeting.
Young investigators are encouraged to join the network and to take leading positions. This contributes to have an interesting knowledge-sharing and to exchange experiences regarding clinical trials and support them for their own projects.
The aim of the Oncodistinct Translational research group is to:
The Oncodistinct Patient Advisory Panel (OPAP) aims to provide researchers and physician-investigators with another perspective on issues related to oncology research.
The mission of OPAP is to improve the relevance and impact of Oncodistinct research projects by involving patients, since the early stages of the development of clinical research protocols. Composed of patients, the main activities of OPAP imply to review and collect opinions on research protocols under development, and to proofread patient information documents and consent forms.
ONCODISTINCT. Accelerating Oncology drug Development and Innovative strategies in Clinical Trials
© Oncodictinct 2024 – Privacy policy